Skip to content

Study · Non-randomized trial · 1992

6 results

Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis.

Sileghem A, Geusens P, Dequeker J

Annals of the rheumatic diseases1 Jun 1992Cited by 20 (Europe PMC)

PMID1616360 (opens in a new tab)PMCIDPMC1004742 (opens in a new tab)DOI10.1136/ard.51.6.761 (opens in a new tab)PepBankPUB-01616360
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with rheumatoid arthritis, salmon calcitonin reduced morning stiffness after two and four months.

    In plain wordsIn women with rheumatoid arthritis, salmon calcitonin reduced morning stiffness.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseMorning stiffness
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 2 and 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Morning stiffness was reduced in the group treated with salmon calcitonin after two and four months.
    2 context sentences
    Summary · context
    The effect of intranasal salmon calcitonin on pain, erosion progression, and bone loss in 40 women with rheumatoid arthritis was investigated.
    Summary · context
    The study design was double blind, placebo controlled for the first four months and open for the next 36 months, allowing for cross over to active drug treatment or to the control group.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with rheumatoid arthritis, calcitonin did not significantly affect erosion progression, with monthly Larsen scores of 0.21 (0.22) versus 0.23 (0.28).

    In plain wordsIn women with rheumatoid arthritis, calcitonin did not significantly change erosion progression compared with control.

    Peptide
    Calcitonin-salmon
    Outcome
    No significant changeErosion progression
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · Average 28 monthsAs given in this study (human).

    Measurements

    Monthly Larsen score progression
    0.21 Larsen score/month
    calcitonin group, SD 0.22
    Monthly Larsen score progression
    0.23 Larsen score/month
    control group, SD 0.28

    Source sentences

    Summary
    After an average follow up of 28 months no significant effect on erosion progression was observed using the Larsen score. The mean (SD) monthly progressions in the Larsen score in the calcitonin and control groups were 0.21 (0.22) and 0.23 (0.28) respectively.
    2 context sentences
    Summary · context
    The effect of intranasal salmon calcitonin on pain, erosion progression, and bone loss in 40 women with rheumatoid arthritis was investigated.
    Summary · context
    The study design was double blind, placebo controlled for the first four months and open for the next 36 months, allowing for cross over to active drug treatment or to the control group.
  3. 03HumanNon-randomized trialEfficacy outcome

    In women with rheumatoid arthritis, nasal calcitonin increased lumbar spine bone mineral density by 1%, while control lost 2%/year.

    In plain wordsIn women with rheumatoid arthritis, nasal calcitonin increased spinal bone density, while control lost bone.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseLumbar spine bone mineral density
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 12 monthsAs given in this study (human).

    Measurements

    Lumbar spine bone mineral density change
    1%
    nasal calcitonin group
    Lumbar spine bone mineral density change
    −2 %/year
    control group

    Source sentences

    Summary
    In contrast, the group receiving nasal calcitonin gained 1% in bone mineral density at the lumbar spine and no loss at the radius distal third.
    3 context sentences
    Summary · context
    During the 12 months of follow up the control group lost bone at a rate of 2%/year at the spine and 4.8%/year at the radius distal third.
    Summary · context
    The effect of intranasal salmon calcitonin on pain, erosion progression, and bone loss in 40 women with rheumatoid arthritis was investigated.
    Summary · context
    The study design was double blind, placebo controlled for the first four months and open for the next 36 months, allowing for cross over to active drug treatment or to the control group.
  4. 04HumanNon-randomized trialEfficacy outcome

    In women with rheumatoid arthritis, the nasal calcitonin group had no loss of bone mineral density at the distal third of the radius, while the control group lost 4.8%/year.

    In plain wordsIn women with rheumatoid arthritis, the nasal calcitonin group had no radius bone loss, while the control group lost bone.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseRadius distal third bone mineral density
    Study

    n: not reported in source

    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · 12 monthsAs given in this study (human).

    Measurements

    Radius distal third bone mineral density change
    −4.8 %/year
    control group

    Source sentences

    Summary
    In contrast, the group receiving nasal calcitonin gained 1% in bone mineral density at the lumbar spine and no loss at the radius distal third.
    3 context sentences
    Summary · context
    During the 12 months of follow up the control group lost bone at a rate of 2%/year at the spine and 4.8%/year at the radius distal third.
    Summary · context
    The effect of intranasal salmon calcitonin on pain, erosion progression, and bone loss in 40 women with rheumatoid arthritis was investigated.
    Summary · context
    The study design was double blind, placebo controlled for the first four months and open for the next 36 months, allowing for cross over to active drug treatment or to the control group.
  5. 05HumanNon-randomized trialEfficacy outcome

    In women with rheumatoid arthritis, spinal bone density declined by 1.8%/year in the second year of calcitonin treatment.

    In plain wordsIn women with rheumatoid arthritis, spinal bone density declined during the second year of calcitonin treatment.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSpinal bone density in second year
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · Second yearAs given in this study (human).

    Measurements

    Spinal bone mineral density change in second year
    −1.8 %/year
    calcitonin group

    Source sentences

    Summary
    The increase in bone density at the spine in the calcitonin group was not sustained and a loss of 1.8%/year was observed in the second year.
    2 context sentences
    Summary · context
    The effect of intranasal salmon calcitonin on pain, erosion progression, and bone loss in 40 women with rheumatoid arthritis was investigated.
    Summary · context
    The study design was double blind, placebo controlled for the first four months and open for the next 36 months, allowing for cross over to active drug treatment or to the control group.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women with rheumatoid arthritis, the difference in spinal bone mineral density between the calcitonin and placebo groups remained significant in the second year, although the calcitonin group lost 1.8%/year.

    In plain wordsIn women with rheumatoid arthritis, the spinal bone density difference between calcitonin and placebo remained significant in the second year.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedSpinal bone density difference
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intranasal · Second yearAs given in this study (human).

    Source sentences

    Summary
    The difference with the placebo group remained significant.
    3 context sentences
    Summary · context
    The increase in bone density at the spine in the calcitonin group was not sustained and a loss of 1.8%/year was observed in the second year.
    Summary · context
    The effect of intranasal salmon calcitonin on pain, erosion progression, and bone loss in 40 women with rheumatoid arthritis was investigated.
    Summary · context
    The study design was double blind, placebo controlled for the first four months and open for the next 36 months, allowing for cross over to active drug treatment or to the control group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.